Last update 01 Nov 2024

sPLA2 x p53 x NF-κB

Basic Info

Related Targets
sPLA2p53NF-κB

Related

1
Drugs associated with sPLA2 x p53 x NF-κB
Mepacrine hydrochloride
Target
NF-κB x p53 x sPLA2
Mechanism
NF-κB inhibitors [+2]
Active Org.
Bayer AGBayer AG [+1]
Originator Org.
Bayer AGBayer AG
Active Indication
Giardiasis [+3]
Inactive Indication
Creutzfeldt-Jakob Disease, Sporadic [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.-
First Approval Date01 Jan 1932
6
Clinical Trials associated with sPLA2 x p53 x NF-κB
NCT01844076 / TerminatedPhase 1/2IIT
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:A Phase I/II Investigator-Initiated Clinical Trial
NCT00574483 / WithdrawnPhase 2
An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma
100 Clinical Results associated with sPLA2 x p53 x NF-κB
Login to view more data
100 Translational Medicine associated with sPLA2 x p53 x NF-κB
Login to view more data
0 Patents (Medical) associated with sPLA2 x p53 x NF-κB
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free